معرفی
Dr. Daniel Holden is a Researcher at the Yale School of Medicine's Imaging Research Center, focusing on molecular imaging and neurobiology. His work primarily involves developing and evaluating PET radiotracers for neurological disorders such as Alzheimer's disease, synapse loss, and neuropsychiatric conditions. Key research areas include radiotracer design, nonhuman primate models, and synaptic density assessment. He collaborates with institutions like the National Institutes of Health and pharmaceutical companies to advance translational neuroscience.
Research Interests:
- PET radioligand development for neurodegenerative and psychiatric disorders
- Mechanisms of synaptic dysfunction in Alzheimer's disease
- In vivo imaging of neurotransmitter receptor systems (e.g., mGluR5, sigma-2 receptors)
- Preclinical validation of novel imaging probes
Recent Work Trends:
Dr. Holden's publications emphasize translational research, bridging preclinical studies with clinical applications. Recent efforts focus on:
- Optimizing radiotracers for brain-penetrant imaging of enzymes like GCPII and GSK-3
- Characterizing synaptic markers (SV2A) in psychiatric and neurodegenerative contexts
- Investigating sigma-2 and LPA1 receptors as therapeutic targets
Grants & Labs:
His research leverages funding from NIH grants and industry partnerships, conducted within the Imaging Research Center's advanced molecular imaging facilities. Collaborations include teams at the Yale Department of Radiology and the School of Pharmacy.